Table III.
Univariate analysis with regard to the 3-year survival rate.
| 3-year survival rate | ||||
|---|---|---|---|---|
| Clinical features | Patients, n | Patients, n | Survival rate, % | P-value |
| Total | 98 | 55 | 56.1 | |
| Sex | 0.149 | |||
| Male | 55 | 34 | 61.9 | |
| Female | 43 | 21 | 44.2 | |
| Age, years | 0.866 | |||
| <60 | 45 | 25 | 55.6 | |
| ≥60 | 53 | 30 | 56.6 | |
| Tumor location | 0.261 | |||
| Central | 39 | 19 | 48.7 | |
| Peripheral | 59 | 36 | 61.0 | |
| Histological type | 0.060 | |||
| SCC | 52 | 33 | 63.5 | |
| ADC | 46 | 22 | 47.8 | |
| Differentiation | 0.033 | |||
| Well | 15 | 11 | 72.7 | |
| Moderately | 51 | 32 | 62.7 | |
| Poorly | 32 | 12 | 37.5 | |
| pT | 0.002 | |||
| pT1 | 11 | 11 | 100 | |
| pT2 | 73 | 39 | 53.4 | |
| pT3 | 14 | 5 | 35.7 | |
| pN | 0.001 | |||
| − | 30 | 28 | 93.3 | |
| + | 68 | 27 | 39.7 | |
| pTNM | 0.001 | |||
| pI | 24 | 22 | 91.7 | |
| pII | 52 | 27 | 51.9 | |
| pIIIa | 22 | 6 | 27.3 | |
| Chemotherapy | 0.636 | |||
| No | 24 | 14 | 58.3 | |
| Yes | 74 | 41 | 55.4 | |
| Radiotherapy | 0.939 | |||
| No | 73 | 42 | 57.5 | |
| Yes | 25 | 13 | 52.0 | |
| EGFR-TKI therapy | 0.152 | |||
| No | 78 | 47 | 60.3 | |
| Yes | 20 | 8 | 40.0 | |
| STAT3 | 0.278 | |||
| − | 16 | 11 | 68.8 | |
| + | 82 | 44 | 53.7 | |
| p-STAT3 | 0.001 | |||
| − | 47 | 35 | 74.5 | |
| + | 51 | 20 | 39.2 | |
| MUC1 | 0.019 | |||
| − | 37 | 26 | 70.3 | |
| + | 61 | 29 | 47.5 | |
SCC, squamous cell carcinoma; ADC, adenocarcinoma; pT, pathological tumor; pN, pathological lymph nodes; pTNM, pathological Tumor-Node-Metastasis; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; p-, phosphorylated; STAT3, signal transducer and activator of transcription 3; MUC1, mucin 1.